Safety and Pharmacologic Study of VTX-2337 in Patients With Advanced Cancer

Completed · Phase 1

Conditions studied: Advanced Solid Tumors, Lymphoma

In brief

This is a multi-center, Phase I study of a new investigational drug, VTX-2337, that may stimulate the immune system to help fight cancer. The purpose of the study is to assess the safety of the investigational drug and to identify the highest dose that is well-tolerated. The pharmacology of VTX-2337 will also be evaluated.

Key facts

Study ID: NCT00688415
Run by: Celgene
People needed: 33
Starts: 2008-11-07
Expected to finish: 2010-11-01
Last updated by the study team: 2019-09-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Ability and willingness to provide written informed consent
Histologically or cytologically confirmed solid tumors or lymphoma
Locally advanced or metastatic disease
Life expectancy of at least 16 weeks
ECOG performance status of 0 or 1
Acceptable physical exam and laboratory tests at study entry
Willingness to use medically acceptable contraception
A negative serum pregnancy test for women with reproductive potential

You may not qualify if…

Anticancer therapy within 2 weeks
Treatment with an investigational agent within 4 weeks
Systemic corticosteroids within 2 weeks or a requirement for systemic immunosuppressive therapy
Known brain metastases unless stable for at least 28 days
Active autoimmune disease
Insulin-dependent diabetes mellitus
Clinically significant cardiac disease within 6 months
Significant infection or fever within 1 week
Pregnant or breast-feeding females
Other conditions or circumstances that could interfere with the study

Where it is running

Mayo Clinic — Scottsdale, Arizona, United States
Scottsdale Healthcare — Scottsdale, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.